Document is current
Any future updates will be listed below
-
Authors
Wright, Katharine M.
DiNapoli, Sarah R. https://orcid.org/0000-0002-3675-9030
Miller, Michelle S. https://orcid.org/0000-0003-1972-4503
Aitana Azurmendi, P.
Zhao, Xiaowei
Yu, Zhiheng
Chakrabarti, Mayukh https://orcid.org/0000-0003-2653-9728
Shi, WuXian
Douglass, Jacqueline
Hwang, Michael S.
Hsiue, Emily Han-Chung
Mog, Brian J. https://orcid.org/0000-0001-9988-7147
Pearlman, Alexander H. https://orcid.org/0000-0002-3504-7517
Paul, Suman https://orcid.org/0000-0001-9357-3702
Konig, Maximilian F. https://orcid.org/0000-0001-5045-5255
Pardoll, Drew M.
Bettegowda, Chetan https://orcid.org/0000-0001-9991-7123
Papadopoulos, Nickolas https://orcid.org/0000-0001-7135-7451
Kinzler, Kenneth W.
Vogelstein, Bert https://orcid.org/0000-0003-0766-3854
Zhou, Shibin https://orcid.org/0000-0003-1941-4425
Gabelli, Sandra B. https://orcid.org/0000-0003-1205-5204
-
Funding
Funding for this research was provided by:
Lustgarten Foundation
- License Information
-
More Information
Article History
Received: 3 September 2022
Accepted: 10 August 2023
First Online: 21 August 2023
Competing interests
: The Johns Hopkins University has filed patent applications related to technologies described in this paper on which E.H.H., K.M.W., J.D., B.J.M., N.P., K.W.K., B.V., S.B.G. and S.Z. are listed as inventors: HLA-restricted epitopes encoded by somatically mutated genes (US20180086832A1), MANAbodies and methods of using (US20200079854A1), MANAbodies targeting tumor antigens and methods of using (PCT/US2020/065617). B.V., K.W.K. and N.P. are founders of Thrive Earlier Detection, an Exact Sciences Company. K.W.K. and N.P. are consultants to Thrive Earlier Detection. B.V., K.W.K., N.P. and S.Z. hold equity in Exact Sciences. B.V., K.W.K., N.P. and S.Z. are founders of, hold equity in, and serve as consultants to ManaT Bio. B.V., K.W.K., N.P. and S.Z. are founders of, hold equity in, and serve as consultants to Personal Genome Diagnostics. K.W.K., B.V., S.Z. and N.P. are consultants to and hold equity in NeoPhore. K.W.K. and N.P. are consultants to and own equity in Haystack Oncology. K.W.K., B.V., and N.P. hold equity in and are consultants to CAGE Pharma. B.V. is a consultant to and holds equity in Catalio Capital Management and may be a consultant to and hold equity in Haystack Oncology. S.Z. has a research agreement with BioMed Valley Discoveries, Inc. C.B. is a consultant to Depuy-Synthes, Galectin Therapeutics, Haystack Oncology, Privo Technologies and Bionaut Labs. C.B. is a co-founder of OrisDx. Patent applications on the work described in this abstract may be filed by Johns Hopkins University. The terms of all these arrangements are being managed by Johns Hopkins University in accordance with its conflict of interest policies. S.B.G. is a founder and holds equity in AMS, LLC.. M.F.K. received consulting fees from Argenx. D.M.P. reports grant and patent royalties through institution from BMS, grant from Compugen, stock from Trieza Therapeutics and Dracen Pharmaceuticals, and founder equity from Potenza; being a consultant for Aduro Biotech, Amgen, Astra Zeneca (Medimmune/Amplimmune), Bayer, DNAtrix, Dynavax Technologies Corporation, Ervaxx, FLX Bio, Rock Springs Capital, Janssen, Merck, Tizona, and Immunomic- Therapeutics; being on the scientific advisory board of Five Prime Therapeutics, Camden Nexus II, WindMil; being on the board of directors for Dracen Pharmaceuticals. The remaining authors declare no competing interests.
